Partnering 2030 & Top Pharma rankings

The session introduced the Partnering 2030 program, covering the key findings, and top pharma rankings for 2024.

HIGHLIGHTS

• 00:16 - Survey participation and reach
• 03:37 - Survey highlights 2022–24
• 34:56 - 2024 top pharma rankings
• 39:13 - Audience Q&A

Key talking points & themes

Challenges in Identifying Innovation

A major challenge for 64% of biopharma companies is finding innovation. While many in the industry believe AI could be a game-changer, research institutes remain skeptical, with 60% indicating that AI has had a neutral impact on tech transfer.

Evolving Trends in Partnering

Co-development and co-promotion deals are favored by smaller biotechs, reflecting their need for collaboration and external resources. Mid-sized companies are becoming more attractive partners due to their accessibility and fewer bureaucratic hurdles compared to large pharma, making them increasingly sought after by biotech companies.

Difficulties in Partner Matching

One of the biggest hurdles in the partnering process is finding the right person to contact within an organization. A striking 61% of participants identified this as a challenge, with some companies even reporting conflicting responses from different departments regarding the same asset.

Communication and Transparency Issues

There is a clear need for better communication between biotechs, research institutes, and large pharma companies. Many smaller organizations express frustration at the lack of feedback from larger partners, often feeling ignored or left without an explanation when a partnership doesn’t move forward.

Importance of Feedback in Partnerships

Feedback is considered vital by both biotechs and research institutes when engaging with larger companies. Providing clear feedback, even when declining an opportunity, is seen as a key factor in building long-term relationships and improving future collaborations.